
What smart money is saying about Merck & Co., Inc.
2 funds in our archive have pitched Merck & Co., Inc. — most recently Baron Health Care Fund in March 2026.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Get an email when a fund writes about it
Position history
Between Q4 2025 and Q2 2026, 3 fund letters reported a position in Merck & Co., Inc. — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 2 | 0 | 0 | 0 |
| Q1 2026 | 1 | 1 | 0 | 1 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Fund activity · 3 positions · 1 move
- HoldsRoyal London AM Global Equity Income FundJune 2026
“Merck & Co., Inc. 1.94”
Read the letterMerck & Co., Inc. - HoldsBaron Health Care FundJune 2026
“We sold Apogee Therapeutics, Inc. and Terns Pharmaceuticals, Inc. following announcements that they were being acquired, Apogee by AbbVie Inc. and Terns by Merck & Co., Inc. , another Fund holding .”
Read the letterMerck & Co., Inc. - AddedBA Beutel Goodman U.S. Value FundMarch 2026
“We also trimmed our positions in Kimberly-Clark, Applied Materials, Omnicom, Merck, Ameriprise Financial, Gen Digital, American Express, Carlyle Group, Chubb.”
Read the letterMerck & Co., Inc.
Also mentioned · 1
These funds discuss Merck & Co., Inc. — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedLaughing Water Capital (LW Capital Management, LLC)June 2026
“which could cost $500M-$1B in payments to Merck for co-development agreements, profit sharing on label expansion, cross licensing, etc.”
Read the letterMerck & Co., Inc.
Fund coverage · 2 theses
- Baron Health Care FundMarch 2026
Merck is a large pharma company managing the Keytruda patent cliff with acquisitions, pipeline investment, and a discounted valuation.
Read the full thesis - Artisan Value Income StrategyDecember 2025
Merck is a major healthcare company with a deep late-stage pipeline, strong balance sheet, and robust free cash flow that support partnerships, M&A, and capital returns despite concerns over Keytruda’s patent expiry.
Read the full thesis
Read every full thesis on Merck & Co., Inc.
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→